Genmab A/S Sponsored ADR (NASDAQ:GMAB) Shares Purchased by Envestnet Asset Management Inc.

Envestnet Asset Management Inc. boosted its holdings in Genmab A/S Sponsored ADR (NASDAQ:GMAB) by 1.7% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 736,326 shares of the company’s stock after buying an additional 12,545 shares during the quarter. Envestnet Asset Management Inc. owned 0.11% of Genmab A/S worth $14,417,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in GMAB. EverSource Wealth Advisors LLC boosted its position in shares of Genmab A/S by 295.3% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company’s stock valued at $26,000 after purchasing an additional 939 shares during the period. Barclays PLC boosted its position in shares of Genmab A/S by 1,072.8% in the 4th quarter. Barclays PLC now owns 2,498 shares of the company’s stock valued at $52,000 after purchasing an additional 2,285 shares during the period. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Genmab A/S in the 4th quarter valued at $60,000. Aquatic Capital Management LLC acquired a new position in shares of Genmab A/S in the 4th quarter valued at $114,000. Finally, Blue Trust Inc. boosted its position in shares of Genmab A/S by 169.9% in the 1st quarter. Blue Trust Inc. now owns 7,413 shares of the company’s stock valued at $145,000 after purchasing an additional 4,666 shares during the period. Institutional investors and hedge funds own 7.07% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on GMAB shares. HC Wainwright reiterated a “buy” rating and set a $37.00 price objective (down from $50.00) on shares of Genmab A/S in a research report on Wednesday, April 9th. Wall Street Zen upgraded shares of Genmab A/S from a “hold” rating to a “buy” rating in a research report on Saturday, July 12th. Truist Financial raised their price objective on Genmab A/S from $45.00 to $46.00 and gave the stock a “buy” rating in a research report on Tuesday, July 8th. Finally, Sanford C. Bernstein lowered Genmab A/S from a “market perform” rating to an “underperform” rating in a research report on Tuesday, April 1st. One analyst has rated the stock with a sell rating, three have given a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $37.80.

Genmab A/S Trading Down 0.6%

Shares of NASDAQ GMAB opened at $21.88 on Friday. Genmab A/S Sponsored ADR has a one year low of $17.24 and a one year high of $28.56. The firm has a market capitalization of $14.04 billion, a PE ratio of 12.43, a PEG ratio of 6.69 and a beta of 0.94. The business has a 50-day moving average price of $21.18 and a two-hundred day moving average price of $20.78.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings results on Thursday, May 8th. The company reported $0.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.23 by $0.08. The business had revenue of $715.00 million during the quarter, compared to analyst estimates of $5.17 billion. Genmab A/S had a return on equity of 18.08% and a net margin of 35.11%. Research analysts anticipate that Genmab A/S Sponsored ADR will post 1.45 EPS for the current year.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.